Assessment of serum galectin-3, methylated arginine and Hs-CRP levels in type 2 diabetes and prediabetes
Galectin-3 is associated with the process of inflammation and fibrosis. The aim of this study was both to evaluate of galectin-3, methylated arginines and hs-CRP in subjects with type 2 diabetes and prediabetes and to investigate a relation between serum galectin-3, methylated arginines and hs-CRP l...
Saved in:
| Published in | Life sciences (1973) Vol. 231; p. 116577 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Inc
15.08.2019
Elsevier BV |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0024-3205 1879-0631 1879-0631 |
| DOI | 10.1016/j.lfs.2019.116577 |
Cover
| Abstract | Galectin-3 is associated with the process of inflammation and fibrosis. The aim of this study was both to evaluate of galectin-3, methylated arginines and hs-CRP in subjects with type 2 diabetes and prediabetes and to investigate a relation between serum galectin-3, methylated arginines and hs-CRP levels.
In this study, all subjects were defined as the control group, type 2 diabetes (n = 84) by fasting plasma glucose and prediabetes (n = 34) by 75-g oral glucose tolerance test. Also, participants with type 2 diabetes were divided into as group I (HbA1c ≤7%, n = 40) and group II (HbA1c ≥7%, n = 44). The analysis of serum methylated arginines levels was analyzed by tandem mass spectrometry. Galectin-3 levels were determined via chemiluminescent microparticle immunoassay (CMIA).
Serum galectin-3, ADMA, L-NMMA and SDMA levels were significantly lower in the control group (13.3 ± 3.42; 0.630 (0.13–1.36); 0.176 (0.02–0.53); 0.115 (0.04–0.26), respectively) compared to diabetic subjects (15.71 ± 4.22; 0.825 (0.23–2.80); 0.366 (0.08–1.41); 0.1645 (0.06–0.47), p = 0.002, p = 0.01, p = 0.001 and p = 0.006, respectively). Galectin-3 was positively correlated with hs-CRP (r = 0.295 p = 0.001), L-NMMA (r = 0.181 p = 0.022), HbA1c (r = 0.247 p = 0.002), neopterin (r = 0.160 p = 0.045) and FPG (r = 0.207 p = 0.001) respectively. Also, there was positively correlated ADMA with FPG (r = 0.192 p = 0.016) and eAG (r = 0.235 p = 0.003).
Thus, galectin-3 might be a useful prognostic marker in the population with prediabetes and diabetes. Moreover, it can be a marker showing the condition of developing complications in diabetic patients.
•Galectin-3, methylated arginines and hs-CRP in subjects with type 2 diabetes and prediabetes•The levels of these biomarkers were found higher in participants with type 2 diabetes.•The levels of these molecules may be used to identify the subjects predisposed to diabetes. |
|---|---|
| AbstractList | Purpose Galectin-3 is associated with the process of inflammation and fibrosis. The aim of this study was both to evaluate of galectin-3, methylated arginines and hs-CRP in subjects with type 2 diabetes and prediabetes and to investigate a relation between serum galectin-3, methylated arginines and hs-CRP levels. Methods In this study, all subjects were defined as the control group, type 2 diabetes (n = 84) by fasting plasma glucose and prediabetes (n = 34) by 75-g oral glucose tolerance test. Also, participants with type 2 diabetes were divided into as group I (HbA1c ≤7%, n = 40) and group II (HbA1c ≥7%, n = 44). The analysis of serum methylated arginines levels was analyzed by tandem mass spectrometry. Galectin-3 levels were determined via chemiluminescent microparticle immunoassay (CMIA). Results Serum galectin-3, ADMA, L-NMMA and SDMA levels were significantly lower in the control group (13.3 ± 3.42; 0.630 (0.13–1.36); 0.176 (0.02–0.53); 0.115 (0.04–0.26), respectively) compared to diabetic subjects (15.71 ± 4.22; 0.825 (0.23–2.80); 0.366 (0.08–1.41); 0.1645 (0.06–0.47), p = 0.002, p = 0.01, p = 0.001 and p = 0.006, respectively). Galectin-3 was positively correlated with hs-CRP (r = 0.295 p = 0.001), L-NMMA (r = 0.181 p = 0.022), HbA1c (r = 0.247 p = 0.002), neopterin (r = 0.160 p = 0.045) and FPG (r = 0.207 p = 0.001) respectively. Also, there was positively correlated ADMA with FPG (r = 0.192 p = 0.016) and eAG (r = 0.235 p = 0.003). Conclusions Thus, galectin-3 might be a useful prognostic marker in the population with prediabetes and diabetes. Moreover, it can be a marker showing the condition of developing complications in diabetic patients. Galectin-3 is associated with the process of inflammation and fibrosis. The aim of this study was both to evaluate of galectin-3, methylated arginines and hs-CRP in subjects with type 2 diabetes and prediabetes and to investigate a relation between serum galectin-3, methylated arginines and hs-CRP levels. In this study, all subjects were defined as the control group, type 2 diabetes (n = 84) by fasting plasma glucose and prediabetes (n = 34) by 75-g oral glucose tolerance test. Also, participants with type 2 diabetes were divided into as group I (HbA1c ≤7%, n = 40) and group II (HbA1c ≥7%, n = 44). The analysis of serum methylated arginines levels was analyzed by tandem mass spectrometry. Galectin-3 levels were determined via chemiluminescent microparticle immunoassay (CMIA). Serum galectin-3, ADMA, L-NMMA and SDMA levels were significantly lower in the control group (13.3 ± 3.42; 0.630 (0.13–1.36); 0.176 (0.02–0.53); 0.115 (0.04–0.26), respectively) compared to diabetic subjects (15.71 ± 4.22; 0.825 (0.23–2.80); 0.366 (0.08–1.41); 0.1645 (0.06–0.47), p = 0.002, p = 0.01, p = 0.001 and p = 0.006, respectively). Galectin-3 was positively correlated with hs-CRP (r = 0.295 p = 0.001), L-NMMA (r = 0.181 p = 0.022), HbA1c (r = 0.247 p = 0.002), neopterin (r = 0.160 p = 0.045) and FPG (r = 0.207 p = 0.001) respectively. Also, there was positively correlated ADMA with FPG (r = 0.192 p = 0.016) and eAG (r = 0.235 p = 0.003). Thus, galectin-3 might be a useful prognostic marker in the population with prediabetes and diabetes. Moreover, it can be a marker showing the condition of developing complications in diabetic patients. Galectin-3 is associated with the process of inflammation and fibrosis. The aim of this study was both to evaluate of galectin-3, methylated arginines and hs-CRP in subjects with type 2 diabetes and prediabetes and to investigate a relation between serum galectin-3, methylated arginines and hs-CRP levels. In this study, all subjects were defined as the control group, type 2 diabetes (n = 84) by fasting plasma glucose and prediabetes (n = 34) by 75-g oral glucose tolerance test. Also, participants with type 2 diabetes were divided into as group I (HbA1c ≤7%, n = 40) and group II (HbA1c ≥7%, n = 44). The analysis of serum methylated arginines levels was analyzed by tandem mass spectrometry. Galectin-3 levels were determined via chemiluminescent microparticle immunoassay (CMIA). Serum galectin-3, ADMA, L-NMMA and SDMA levels were significantly lower in the control group (13.3 ± 3.42; 0.630 (0.13–1.36); 0.176 (0.02–0.53); 0.115 (0.04–0.26), respectively) compared to diabetic subjects (15.71 ± 4.22; 0.825 (0.23–2.80); 0.366 (0.08–1.41); 0.1645 (0.06–0.47), p = 0.002, p = 0.01, p = 0.001 and p = 0.006, respectively). Galectin-3 was positively correlated with hs-CRP (r = 0.295 p = 0.001), L-NMMA (r = 0.181 p = 0.022), HbA1c (r = 0.247 p = 0.002), neopterin (r = 0.160 p = 0.045) and FPG (r = 0.207 p = 0.001) respectively. Also, there was positively correlated ADMA with FPG (r = 0.192 p = 0.016) and eAG (r = 0.235 p = 0.003). Thus, galectin-3 might be a useful prognostic marker in the population with prediabetes and diabetes. Moreover, it can be a marker showing the condition of developing complications in diabetic patients. •Galectin-3, methylated arginines and hs-CRP in subjects with type 2 diabetes and prediabetes•The levels of these biomarkers were found higher in participants with type 2 diabetes.•The levels of these molecules may be used to identify the subjects predisposed to diabetes. Galectin-3 is associated with the process of inflammation and fibrosis. The aim of this study was both to evaluate of galectin-3, methylated arginines and hs-CRP in subjects with type 2 diabetes and prediabetes and to investigate a relation between serum galectin-3, methylated arginines and hs-CRP levels.PURPOSEGalectin-3 is associated with the process of inflammation and fibrosis. The aim of this study was both to evaluate of galectin-3, methylated arginines and hs-CRP in subjects with type 2 diabetes and prediabetes and to investigate a relation between serum galectin-3, methylated arginines and hs-CRP levels.In this study, all subjects were defined as the control group, type 2 diabetes (n = 84) by fasting plasma glucose and prediabetes (n = 34) by 75-g oral glucose tolerance test. Also, participants with type 2 diabetes were divided into as group I (HbA1c ≤7%, n = 40) and group II (HbA1c ≥7%, n = 44). The analysis of serum methylated arginines levels was analyzed by tandem mass spectrometry. Galectin-3 levels were determined via chemiluminescent microparticle immunoassay (CMIA).METHODSIn this study, all subjects were defined as the control group, type 2 diabetes (n = 84) by fasting plasma glucose and prediabetes (n = 34) by 75-g oral glucose tolerance test. Also, participants with type 2 diabetes were divided into as group I (HbA1c ≤7%, n = 40) and group II (HbA1c ≥7%, n = 44). The analysis of serum methylated arginines levels was analyzed by tandem mass spectrometry. Galectin-3 levels were determined via chemiluminescent microparticle immunoassay (CMIA).Serum galectin-3, ADMA, L-NMMA and SDMA levels were significantly lower in the control group (13.3 ± 3.42; 0.630 (0.13-1.36); 0.176 (0.02-0.53); 0.115 (0.04-0.26), respectively) compared to diabetic subjects (15.71 ± 4.22; 0.825 (0.23-2.80); 0.366 (0.08-1.41); 0.1645 (0.06-0.47), p = 0.002, p = 0.01, p = 0.001 and p = 0.006, respectively). Galectin-3 was positively correlated with hs-CRP (r = 0.295 p = 0.001), L-NMMA (r = 0.181 p = 0.022), HbA1c (r = 0.247 p = 0.002), neopterin (r = 0.160 p = 0.045) and FPG (r = 0.207 p = 0.001) respectively. Also, there was positively correlated ADMA with FPG (r = 0.192 p = 0.016) and eAG (r = 0.235 p = 0.003).RESULTSSerum galectin-3, ADMA, L-NMMA and SDMA levels were significantly lower in the control group (13.3 ± 3.42; 0.630 (0.13-1.36); 0.176 (0.02-0.53); 0.115 (0.04-0.26), respectively) compared to diabetic subjects (15.71 ± 4.22; 0.825 (0.23-2.80); 0.366 (0.08-1.41); 0.1645 (0.06-0.47), p = 0.002, p = 0.01, p = 0.001 and p = 0.006, respectively). Galectin-3 was positively correlated with hs-CRP (r = 0.295 p = 0.001), L-NMMA (r = 0.181 p = 0.022), HbA1c (r = 0.247 p = 0.002), neopterin (r = 0.160 p = 0.045) and FPG (r = 0.207 p = 0.001) respectively. Also, there was positively correlated ADMA with FPG (r = 0.192 p = 0.016) and eAG (r = 0.235 p = 0.003).Thus, galectin-3 might be a useful prognostic marker in the population with prediabetes and diabetes. Moreover, it can be a marker showing the condition of developing complications in diabetic patients.CONCLUSIONSThus, galectin-3 might be a useful prognostic marker in the population with prediabetes and diabetes. Moreover, it can be a marker showing the condition of developing complications in diabetic patients. Galectin-3 is associated with the process of inflammation and fibrosis. The aim of this study was both to evaluate of galectin-3, methylated arginines and hs-CRP in subjects with type 2 diabetes and prediabetes and to investigate a relation between serum galectin-3, methylated arginines and hs-CRP levels. In this study, all subjects were defined as the control group, type 2 diabetes (n = 84) by fasting plasma glucose and prediabetes (n = 34) by 75-g oral glucose tolerance test. Also, participants with type 2 diabetes were divided into as group I (HbA1c ≤7%, n = 40) and group II (HbA1c ≥7%, n = 44). The analysis of serum methylated arginines levels was analyzed by tandem mass spectrometry. Galectin-3 levels were determined via chemiluminescent microparticle immunoassay (CMIA). Serum galectin-3, ADMA, L-NMMA and SDMA levels were significantly lower in the control group (13.3 ± 3.42; 0.630 (0.13-1.36); 0.176 (0.02-0.53); 0.115 (0.04-0.26), respectively) compared to diabetic subjects (15.71 ± 4.22; 0.825 (0.23-2.80); 0.366 (0.08-1.41); 0.1645 (0.06-0.47), p = 0.002, p = 0.01, p = 0.001 and p = 0.006, respectively). Galectin-3 was positively correlated with hs-CRP (r = 0.295 p = 0.001), L-NMMA (r = 0.181 p = 0.022), HbA1c (r = 0.247 p = 0.002), neopterin (r = 0.160 p = 0.045) and FPG (r = 0.207 p = 0.001) respectively. Also, there was positively correlated ADMA with FPG (r = 0.192 p = 0.016) and eAG (r = 0.235 p = 0.003). Thus, galectin-3 might be a useful prognostic marker in the population with prediabetes and diabetes. Moreover, it can be a marker showing the condition of developing complications in diabetic patients. |
| ArticleNumber | 116577 |
| Author | İpekçi, Süleyman Hilmi Baldane, Süleyman Atalar, Mehmet Nuri Ünlü, Ali Kebapcılar, Levent Abuşoğlu, Sedat Tok, Oğuzhan |
| Author_xml | – sequence: 1 givenname: Mehmet Nuri orcidid: 0000-0003-2993-2605 surname: Atalar fullname: Atalar, Mehmet Nuri email: mnuri.atalar@igdir.edu.tr organization: Iğdır University, Department of Biochemistry, Faculty of Arts and Science, Iğdır, Turkey – sequence: 2 givenname: Sedat surname: Abuşoğlu fullname: Abuşoğlu, Sedat organization: Department of Biochemistry, Selcuk University Faculty of Medicine, Konya, Turkey – sequence: 3 givenname: Ali surname: Ünlü fullname: Ünlü, Ali organization: Department of Biochemistry, Selcuk University Faculty of Medicine, Konya, Turkey – sequence: 4 givenname: Oğuzhan surname: Tok fullname: Tok, Oğuzhan organization: Department of Biochemistry, Selcuk University Faculty of Medicine, Konya, Turkey – sequence: 5 givenname: Süleyman Hilmi surname: İpekçi fullname: İpekçi, Süleyman Hilmi organization: Department of Endocrinology, Selcuk University Faculty of Medicine, Konya, Turkey – sequence: 6 givenname: Süleyman surname: Baldane fullname: Baldane, Süleyman organization: Department of Endocrinology, Selcuk University Faculty of Medicine, Konya, Turkey – sequence: 7 givenname: Levent surname: Kebapcılar fullname: Kebapcılar, Levent organization: Department of Endocrinology, Selcuk University Faculty of Medicine, Konya, Turkey |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31211997$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkU1rFDEYgINU7Lb6A7xIwEsPzpqPyWSCp7KoFQqK6DlkkjdtlpnMmmQK--_Nut1LD8VTSHieF948F-gszhEQekvJmhLafdyuR5_XjFC1prQTUr5AK9pL1ZCO0zO0IoS1DWdEnKOLnLeEECEkf4XOOWWUKiVX6P46Z8h5gljw7HGGtEz4zoxgS4gN_4AnKPf70RRw2KS7EEMEbKLDN7nZ_PyBR3iAMeMQcdnvADPsghmgQP4H7RKc7q_RS2_GDG8ez0v0-8vnX5ub5vb712-b69vGtrQtjZVAegXSK0-h7jIoDgp65gfR904Zx7jvqCPSk4GBYko6YEY4S6V39YFfoqvj3F2a_yyQi55CtjCOJsK8ZM2Y4Kyjver-A215q6RiB_T9E3Q7LynWRSrVcyU456JS7x6pZZjA6V0Kk0l7ffruCsgjYNOccwKvbSimhDmWZMKoKdGHsHqra1h9CKuPYatJn5in4c85n45OLQQPAZLONkC0tUmqfbWbwzP2X_hOuUU |
| CitedBy_id | crossref_primary_10_5937_jomb0_47180 crossref_primary_10_2217_bmm_2020_0282 crossref_primary_10_5937_jomb0_50471 crossref_primary_10_4103_jod_jod_84_22 crossref_primary_10_1021_acsomega_0c01318 crossref_primary_10_1186_s12933_024_02418_5 crossref_primary_10_2147_JIR_S273858 crossref_primary_10_3390_biomedicines9091159 crossref_primary_10_3390_ijerph19127524 crossref_primary_10_3389_fendo_2023_1189192 crossref_primary_10_1038_s41598_022_20860_x crossref_primary_10_1016_j_ejim_2020_04_025 crossref_primary_10_1080_1354750X_2021_2013539 crossref_primary_10_1007_s11154_021_09704_7 crossref_primary_10_18632_aging_203101 crossref_primary_10_3390_ijms24119721 crossref_primary_10_1007_s10719_024_10152_z crossref_primary_10_1007_s13300_020_00835_9 crossref_primary_10_1111_jdi_13256 crossref_primary_10_22141_2308_2097_58_2_2024_602 crossref_primary_10_1002_jcu_23559 crossref_primary_10_1042_CS20241021 crossref_primary_10_3389_fendo_2022_805837 crossref_primary_10_31083_j_rcm2309320 |
| Cites_doi | 10.1093/glycob/cwu111 10.1016/j.bbrc.2006.03.105 10.1371/journal.pone.0057915 10.1016/j.ahj.2012.05.010 10.2337/dc15-S005 10.1093/glycob/cwj089 10.1007/s40618-014-0222-2 10.1097/00005344-199204002-00018 10.2337/dc14-1140 10.1016/j.bbagen.2005.12.020 10.1007/s10096-013-1919-4 10.4172/2161-1017.1000217 10.2337/db12-0222 10.1038/nature05485 10.3760/cmaj.issn.0366-6999.20130217 10.1515/cclm-2014-0187 10.1161/01.ATV.20.9.2032 10.1016/j.jdiacomp.2011.10.001 10.1016/j.bbi.2019.01.019 10.2337/dc08-0545 10.1177/193229681000400326 10.1016/j.atherosclerosis.2005.05.002 10.1210/jc.2009-1619 10.1016/j.aca.2010.08.011 10.1111/j.1600-065X.2009.00794.x 10.1038/ncb2970 10.1089/met.2011.0044 |
| ContentType | Journal Article |
| Copyright | 2019 Copyright © 2019. Published by Elsevier Inc. Copyright Elsevier BV Aug 15, 2019 |
| Copyright_xml | – notice: 2019 – notice: Copyright © 2019. Published by Elsevier Inc. – notice: Copyright Elsevier BV Aug 15, 2019 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7QR 7TK 7U7 7U9 8FD C1K FR3 H94 P64 RC3 7X8 7S9 L.6 |
| DOI | 10.1016/j.lfs.2019.116577 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Virology and AIDS Abstracts Technology Research Database Toxicology Abstracts AIDS and Cancer Research Abstracts Chemoreception Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | Genetics Abstracts AGRICOLA MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Biology |
| EISSN | 1879-0631 |
| ExternalDocumentID | 31211997 10_1016_j_lfs_2019_116577 S002432051930503X |
| Genre | Journal Article |
| GroupedDBID | --- --K --M -~X .~1 0R~ 1B1 1RT 1~. 4.4 457 5GY 5RE 5VS 6TJ 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXUO ABFNM ABFRF ABJNI ABLJU ABMAC ABMZM ABZDS ACDAQ ACGFO ACGFS ACIUM ACIWK ACPRK ACRLP ADBBV ADEZE AEBSH AEFWE AEIPS AEKER AENEX AFRAH AFTJW AFXIZ AGUBO AGYEJ AIEXJ AIKHN AITUG AJRQY AKRWK ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AXJTR BKOJK BLXMC BNPGV C45 CNWQP CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IH2 IHE J1W K-O KOM L7B M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SDF SDG SDP SES SPCBC SSH SSP SSZ T5K TEORI YZZ ~G- .55 .GJ 29L 3O- 53G AAQXK AAYWO AAYXX ABWVN ABXDB ACIEU ACLOT ACRPL ACVFH ADCNI ADMUD ADNMO AEUPX AFFNX AFJKZ AFPUW AGHFR AGQPQ AHHHB AIGII AIIUN AKBMS AKYEP APXCP ASPBG AVWKF AZFZN CITATION EFKBS EFLBG FEDTE FGOYB G-2 HMG HMT HVGLF HZ~ H~9 J5H MVM R2- SEW SIN SPT WUQ X7M Y6R YYP ZGI ZKB ZXP ZY4 ~HD CGR CUY CVF ECM EIF NPM 7QP 7QR 7TK 7U7 7U9 8FD AGCQF C1K FR3 H94 P64 RC3 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c414t-c7e089e7f9f1e187b93e9e82fb588d9ad23f61d07f0b2e9297de2a5dc17fd2e93 |
| IEDL.DBID | AIKHN |
| ISSN | 0024-3205 1879-0631 |
| IngestDate | Sun Sep 28 01:32:55 EDT 2025 Sat Sep 27 20:03:28 EDT 2025 Wed Aug 13 03:19:45 EDT 2025 Thu Apr 03 07:04:31 EDT 2025 Thu Sep 25 00:48:25 EDT 2025 Thu Apr 24 23:03:02 EDT 2025 Sun Apr 06 06:54:16 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Type 2 diabetes Galectin-3 Prediabetes Methylated arginines |
| Language | English |
| License | Copyright © 2019. Published by Elsevier Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c414t-c7e089e7f9f1e187b93e9e82fb588d9ad23f61d07f0b2e9297de2a5dc17fd2e93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-2993-2605 |
| PMID | 31211997 |
| PQID | 2283953335 |
| PQPubID | 2045439 |
| ParticipantIDs | proquest_miscellaneous_2253261896 proquest_miscellaneous_2243497926 proquest_journals_2283953335 pubmed_primary_31211997 crossref_citationtrail_10_1016_j_lfs_2019_116577 crossref_primary_10_1016_j_lfs_2019_116577 elsevier_sciencedirect_doi_10_1016_j_lfs_2019_116577 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-08-15 |
| PublicationDateYYYYMMDD | 2019-08-15 |
| PublicationDate_xml | – month: 08 year: 2019 text: 2019-08-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: New York |
| PublicationTitle | Life sciences (1973) |
| PublicationTitleAlternate | Life Sci |
| PublicationYear | 2019 |
| Publisher | Elsevier Inc Elsevier BV |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier BV |
| References | Chiang, Kirkman, Laffel, Peters (bb0010) 2014 Stajica, Selakovic, Jovicicc, Joksimovic, Arsenijevicd, Lukicd, Rosi (bb0035) 2019; 78 Henderson, Sethi (bb0120) 2009; 230 Nathan, Kuenen, Hui Zheng, Schoenfeld, Robert (bb0080) 2008; 31 Lakshminarayan, Wunder, Becken, Howes, Benzing, Arumugam, Sales, Ariotti, Chambon, Lamaze (bb0130) 2014; 16 Mehmetoğlu, Gökce, Kurban, Gökce, Atalar, Celik (bb0075) 2017; 13 Alrashed, Abougoush, Akgul, Erbil (bb0070) 2002; 44 Vallance, Leone, Calver, Collier, Moncada (bb0155) 1992; 20 Pugliese, Iacobini, Ricci, Fantauzzi, Menini (bb0050) 2014; 52 Yilmaz, Cakmak, Inan, Darcin, Akcay (bb0095) 2015; 38 Choi, Yan, Fernandes (bb0145) 2012; 164 Weigert, Neumeier, Wanninger, Bauer, Farkas, Scherer (bb0100) 2010; 95 ten Oever, Giamarellos-Bourboulis, van de Veerdonk, Stelma, Simon, Janssen, Johnson, Pachot, Kullberg, Joosten, Netea (bb0125) 2013; 32 Sypniewska (bb0015) 2014; 24 American Diabetes Association (bb0065) 2015; 38 Hotamisligil (bb0135) 2006; 444 Di Gangi, Chiandetti, Gucciardi, Moret, Naturale, Gi¬ordano (bb0085) 2010; 677 Asegaonkar, Marathe, Tekade (bb0110) 2011; 25 International Diabetes Federation (bb0005) 2017 Dumic, Dabelic, Flögel (bb0045) 2006; 1760 Pfützner, Schöndorf, Hanefeld, Forst (bb0140) 2010; 4 Wang, Sim, Wang (bb0165) 2006; 184 International Diabetes Federation (bb0020) 2015 Misra, Das, Sahu (bb0105) 2012; 10 Qi-hui, Yu-feng, Tian-lang, Huai-hong, Qiang, Xiao-jun (bb0150) 2013; 126 Li, Davidson, Lin (bb0040) 2006; 16 Berezin (bb0090) 2016; 5 Pang, Rhodes, Pini, Akasheh, Castellanos, Cabay, Cooper, Perretti, Fantuzzi (bb0055) 2013; 8 Wan, Liu (bb0030) 2016; 6 Pugliese, Iacobini, Pesce, Menini (bb0025) 2015; 25 Cooke (bb0160) 2000; 20 Karlsen, Størling, Sparre, Larsen, Mahmood, Størling, Roepstorff, Wrzesinski, Larsen, Fey, Nielsen, Heding, Ricordi, Johannesen, Kristiansen, Christensen, Kockum, Luthman, Nerup, Pociot (bb0060) 2006; 344 Pejnovic, Pantic, Jovanovic, Radosavljevic, Milovanovic, Nikolic, Zdravkovic, Djukic, Arsenijevic, Lukic (bb0115) 2013; 62 Pugliese (10.1016/j.lfs.2019.116577_bb0050) 2014; 52 Weigert (10.1016/j.lfs.2019.116577_bb0100) 2010; 95 Henderson (10.1016/j.lfs.2019.116577_bb0120) 2009; 230 ten Oever (10.1016/j.lfs.2019.116577_bb0125) 2013; 32 Chiang (10.1016/j.lfs.2019.116577_bb0010) 2014 Hotamisligil (10.1016/j.lfs.2019.116577_bb0135) 2006; 444 Di Gangi (10.1016/j.lfs.2019.116577_bb0085) 2010; 677 Asegaonkar (10.1016/j.lfs.2019.116577_bb0110) 2011; 25 Qi-hui (10.1016/j.lfs.2019.116577_bb0150) 2013; 126 Li (10.1016/j.lfs.2019.116577_bb0040) 2006; 16 Pang (10.1016/j.lfs.2019.116577_bb0055) 2013; 8 Choi (10.1016/j.lfs.2019.116577_bb0145) 2012; 164 Karlsen (10.1016/j.lfs.2019.116577_bb0060) 2006; 344 International Diabetes Federation (10.1016/j.lfs.2019.116577_bb0005) 2017 Wang (10.1016/j.lfs.2019.116577_bb0165) 2006; 184 Yilmaz (10.1016/j.lfs.2019.116577_bb0095) 2015; 38 Pugliese (10.1016/j.lfs.2019.116577_bb0025) 2015; 25 Dumic (10.1016/j.lfs.2019.116577_bb0045) 2006; 1760 International Diabetes Federation (10.1016/j.lfs.2019.116577_bb0020) 2015 Pfützner (10.1016/j.lfs.2019.116577_bb0140) 2010; 4 Cooke (10.1016/j.lfs.2019.116577_bb0160) 2000; 20 Stajica (10.1016/j.lfs.2019.116577_bb0035) 2019; 78 Wan (10.1016/j.lfs.2019.116577_bb0030) 2016; 6 Vallance (10.1016/j.lfs.2019.116577_bb0155) 1992; 20 Mehmetoğlu (10.1016/j.lfs.2019.116577_bb0075) 2017; 13 American Diabetes Association (10.1016/j.lfs.2019.116577_bb0065) 2015; 38 Alrashed (10.1016/j.lfs.2019.116577_bb0070) 2002; 44 Misra (10.1016/j.lfs.2019.116577_bb0105) 2012; 10 Berezin (10.1016/j.lfs.2019.116577_bb0090) 2016; 5 Lakshminarayan (10.1016/j.lfs.2019.116577_bb0130) 2014; 16 Pejnovic (10.1016/j.lfs.2019.116577_bb0115) 2013; 62 Nathan (10.1016/j.lfs.2019.116577_bb0080) 2008; 31 Sypniewska (10.1016/j.lfs.2019.116577_bb0015) 2014; 24 |
| References_xml | – volume: 16 start-page: 612 year: 2006 end-page: 622 ident: bb0040 article-title: Transport of galectin-3 between the nucleus and cytoplasm. II. Identification of the signal for nuclear export publication-title: Glycobiology – volume: 20 start-page: 60 year: 1992 end-page: 62 ident: bb0155 article-title: Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis publication-title: J. Cardiovasc. Pharmacol. – volume: 126 start-page: 2109 year: 2013 end-page: 2115 ident: bb0150 article-title: Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus publication-title: Chin. Med. J. – volume: 677 start-page: 140 year: 2010 end-page: 148 ident: bb0085 article-title: Simultaneous quantitative determination of N(G),N(G)-dimethyl-L-arginine or asymmetric dimethylarginine and related pathway's metabolites in biological fluids by ultrahigh-performance liquid chromatography/electrospray ionization-tandem mass specterometry publication-title: Anal. Chim. Acta – volume: 16 start-page: 595 year: 2014 end-page: 606 ident: bb0130 article-title: Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrinindependent carriers publication-title: Nat. Cell Biol. – volume: 10 start-page: 209 year: 2012 end-page: 213 ident: bb0105 article-title: Prevalence of inflammatory markers (high-sensitivity C-reactive protein, nuclear factor-κB and adiponectin) in Indian patients with type 2 diabetes mellitus with and without macrovascular complications publication-title: Metab. Syndr. Relat. Disord. – start-page: 12 year: 2015 end-page: 18 ident: bb0020 article-title: Diabetes Atlas – volume: 44 start-page: 273 year: 2002 end-page: 277 ident: bb0070 article-title: Detection method of serum and urine neopterin levels by high performance liquid chromatography and clinical applications publication-title: Gulhane MJ – volume: 31 start-page: 1473 year: 2008 end-page: 1478 ident: bb0080 article-title: Heine, for the A1c-derived average glucose (ADAG) study group publication-title: Diabetes Care – volume: 38 start-page: 527 year: 2015 end-page: 533 ident: bb0095 article-title: Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor? publication-title: J. Endocrinol. Investig. – volume: 164 start-page: 251 year: 2012 end-page: 258 ident: bb0145 article-title: High-sensitivity C-reactive protein as an independent predictor of progressive myocardial functional deterioration: the multiethnic study of atherosclerosis publication-title: Am. Heart J. – volume: 25 start-page: 368 year: 2011 end-page: 370 ident: bb0110 article-title: High-sensitivity C-reactive protein: a novel cardiovascular risk predictor in type 2 diabetics with normal lipid profile publication-title: J. Diabetes Complicat. – volume: 24 start-page: 1 year: 2014 end-page: 78 ident: bb0015 article-title: Diabetes epidemics-classification and prevalence publication-title: Biochemia Medica – volume: 5 start-page: 1 year: 2016 ident: bb0090 article-title: The rationality to use of galectin-3 as target in biomarker-guided therapy of type 2 diabetes mellitus publication-title: Endocrinol Metab Syndr – volume: 62 start-page: 1932 year: 2013 end-page: 1944 ident: bb0115 article-title: Galectin-3 deficiency accelerates high-fat diet induced obesity and amplifies inflammation in adipose tissue and pancreatic islets publication-title: Diabetes – volume: 52 start-page: 1413 year: 2014 end-page: 1423 ident: bb0050 article-title: Galectin-3 in diabetic patients publication-title: Clin. Chem. Lab. Med. – volume: 8 year: 2013 ident: bb0055 article-title: Increased adiposity, dysregulated glucose metabolism and systemic inflammation in galectin-3 KO mice publication-title: PLoS One – volume: 444 start-page: 860 year: 2006 end-page: 867 ident: bb0135 article-title: Inflammation and metabolic disorders publication-title: Nature – volume: 6 start-page: 1 year: 2016 end-page: 9 ident: bb0030 article-title: Galectin-3 and inflammation glycobiol publication-title: Insights – volume: 4 start-page: 706 year: 2010 end-page: 716 ident: bb0140 article-title: High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone publication-title: J. Diabetes Sci. Technol. – volume: 78 start-page: 177 year: 2019 end-page: 187 ident: bb0035 article-title: The role of galectin-3 in modulation of anxiety state level in mice publication-title: Brain, Behavior, and Immunity journal – volume: 25 start-page: 136 year: 2015 end-page: 150 ident: bb0025 article-title: Galectin-3: an emerging all-out player in metabolic disorders and their complications publication-title: Glycobiology – volume: 13 start-page: 70 year: 2017 end-page: 75 ident: bb0075 article-title: Publication investigation of the relationships ofobesity with melatonin and dehydroepiandrosterone levels publication-title: Nobel Medicus – volume: 38 start-page: S8 year: 2015 end-page: S16 ident: bb0065 article-title: Classification and diagnosis of diabetes. Sec. 2. In standards of medical care in diabetesd-2015 publication-title: Diabetes Care – start-page: 2034 year: 2014 end-page: 2054 ident: bb0010 article-title: Type 1 diabetes through the lifespan: a position statement of the American Diabetes Association publication-title: Diabetes Care – volume: 1760 start-page: 616 year: 2006 end-page: 635 ident: bb0045 article-title: Galectin-3: an open-ended story publication-title: Biochim. Biophys. Acta – volume: 20 start-page: 2032 year: 2000 end-page: 2037 ident: bb0160 article-title: Does ADMA cause endothelial dysfunction? publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 344 start-page: 406 year: 2006 end-page: 415 ident: bb0060 article-title: Immune-mediated beta-cell destruction in vitro and in vivo—a pivotal role for galectin-3 publication-title: Biochem. Biophys. Res. Commun. – volume: 184 start-page: 383 year: 2006 end-page: 388 ident: bb0165 article-title: Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease publication-title: Atherosclerosis – volume: 230 start-page: 160 year: 2009 end-page: 171 ident: bb0120 article-title: The regulation of inflammation by galectin-3 publication-title: Immunol. Rev. – volume: 95 start-page: 1404 year: 2010 end-page: 1411 ident: bb0100 article-title: Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes publication-title: J. Clin. Endocrinol. Metab. – volume: 32 start-page: 1605 year: 2013 end-page: 1610 ident: bb0125 article-title: Circulating galectin-3 in infections and non-infectious inflammatory diseases publication-title: Eur. J. Clin. Microbiol. Infect. Dis. – start-page: 32 year: 2017 end-page: 34 ident: bb0005 article-title: Diabetes Atlas – volume: 25 start-page: 136 issue: 2 year: 2015 ident: 10.1016/j.lfs.2019.116577_bb0025 article-title: Galectin-3: an emerging all-out player in metabolic disorders and their complications publication-title: Glycobiology doi: 10.1093/glycob/cwu111 – volume: 344 start-page: 406 year: 2006 ident: 10.1016/j.lfs.2019.116577_bb0060 article-title: Immune-mediated beta-cell destruction in vitro and in vivo—a pivotal role for galectin-3 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2006.03.105 – start-page: 32 year: 2017 ident: 10.1016/j.lfs.2019.116577_bb0005 – volume: 8 year: 2013 ident: 10.1016/j.lfs.2019.116577_bb0055 article-title: Increased adiposity, dysregulated glucose metabolism and systemic inflammation in galectin-3 KO mice publication-title: PLoS One doi: 10.1371/journal.pone.0057915 – volume: 164 start-page: 251 year: 2012 ident: 10.1016/j.lfs.2019.116577_bb0145 article-title: High-sensitivity C-reactive protein as an independent predictor of progressive myocardial functional deterioration: the multiethnic study of atherosclerosis publication-title: Am. Heart J. doi: 10.1016/j.ahj.2012.05.010 – volume: 24 start-page: 1 issue: Suppl1 year: 2014 ident: 10.1016/j.lfs.2019.116577_bb0015 article-title: Diabetes epidemics-classification and prevalence publication-title: Biochemia Medica – volume: 38 start-page: S8 issue: Suppl. 1 year: 2015 ident: 10.1016/j.lfs.2019.116577_bb0065 article-title: Classification and diagnosis of diabetes. Sec. 2. In standards of medical care in diabetesd-2015 publication-title: Diabetes Care doi: 10.2337/dc15-S005 – volume: 16 start-page: 612 year: 2006 ident: 10.1016/j.lfs.2019.116577_bb0040 article-title: Transport of galectin-3 between the nucleus and cytoplasm. II. Identification of the signal for nuclear export publication-title: Glycobiology doi: 10.1093/glycob/cwj089 – volume: 38 start-page: 527 year: 2015 ident: 10.1016/j.lfs.2019.116577_bb0095 article-title: Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor? publication-title: J. Endocrinol. Investig. doi: 10.1007/s40618-014-0222-2 – volume: 20 start-page: 60 issue: Suppl. 12 year: 1992 ident: 10.1016/j.lfs.2019.116577_bb0155 article-title: Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis publication-title: J. Cardiovasc. Pharmacol. doi: 10.1097/00005344-199204002-00018 – start-page: 2034 year: 2014 ident: 10.1016/j.lfs.2019.116577_bb0010 article-title: Type 1 diabetes through the lifespan: a position statement of the American Diabetes Association publication-title: Diabetes Care doi: 10.2337/dc14-1140 – volume: 1760 start-page: 616 year: 2006 ident: 10.1016/j.lfs.2019.116577_bb0045 article-title: Galectin-3: an open-ended story publication-title: Biochim. Biophys. Acta doi: 10.1016/j.bbagen.2005.12.020 – volume: 32 start-page: 1605 issue: 12 year: 2013 ident: 10.1016/j.lfs.2019.116577_bb0125 article-title: Circulating galectin-3 in infections and non-infectious inflammatory diseases publication-title: Eur. J. Clin. Microbiol. Infect. Dis. doi: 10.1007/s10096-013-1919-4 – volume: 5 start-page: 1 year: 2016 ident: 10.1016/j.lfs.2019.116577_bb0090 article-title: The rationality to use of galectin-3 as target in biomarker-guided therapy of type 2 diabetes mellitus publication-title: Endocrinol Metab Syndr doi: 10.4172/2161-1017.1000217 – volume: 62 start-page: 1932 year: 2013 ident: 10.1016/j.lfs.2019.116577_bb0115 article-title: Galectin-3 deficiency accelerates high-fat diet induced obesity and amplifies inflammation in adipose tissue and pancreatic islets publication-title: Diabetes doi: 10.2337/db12-0222 – volume: 444 start-page: 860 year: 2006 ident: 10.1016/j.lfs.2019.116577_bb0135 article-title: Inflammation and metabolic disorders publication-title: Nature doi: 10.1038/nature05485 – volume: 126 start-page: 2109 issue: 11 year: 2013 ident: 10.1016/j.lfs.2019.116577_bb0150 article-title: Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus publication-title: Chin. Med. J. doi: 10.3760/cmaj.issn.0366-6999.20130217 – volume: 52 start-page: 1413 issue: 10 year: 2014 ident: 10.1016/j.lfs.2019.116577_bb0050 article-title: Galectin-3 in diabetic patients publication-title: Clin. Chem. Lab. Med. doi: 10.1515/cclm-2014-0187 – volume: 20 start-page: 2032 year: 2000 ident: 10.1016/j.lfs.2019.116577_bb0160 article-title: Does ADMA cause endothelial dysfunction? publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/01.ATV.20.9.2032 – volume: 25 start-page: 368 year: 2011 ident: 10.1016/j.lfs.2019.116577_bb0110 article-title: High-sensitivity C-reactive protein: a novel cardiovascular risk predictor in type 2 diabetics with normal lipid profile publication-title: J. Diabetes Complicat. doi: 10.1016/j.jdiacomp.2011.10.001 – volume: 78 start-page: 177 issue: 2019 year: 2019 ident: 10.1016/j.lfs.2019.116577_bb0035 article-title: The role of galectin-3 in modulation of anxiety state level in mice publication-title: Brain, Behavior, and Immunity journal doi: 10.1016/j.bbi.2019.01.019 – volume: 31 start-page: 1473 issue: 8 year: 2008 ident: 10.1016/j.lfs.2019.116577_bb0080 article-title: Heine, for the A1c-derived average glucose (ADAG) study group publication-title: Diabetes Care doi: 10.2337/dc08-0545 – volume: 4 start-page: 706 year: 2010 ident: 10.1016/j.lfs.2019.116577_bb0140 article-title: High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone publication-title: J. Diabetes Sci. Technol. doi: 10.1177/193229681000400326 – volume: 184 start-page: 383 issue: 2 year: 2006 ident: 10.1016/j.lfs.2019.116577_bb0165 article-title: Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2005.05.002 – start-page: 12 year: 2015 ident: 10.1016/j.lfs.2019.116577_bb0020 – volume: 95 start-page: 1404 issue: 3 year: 2010 ident: 10.1016/j.lfs.2019.116577_bb0100 article-title: Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2009-1619 – volume: 677 start-page: 140 year: 2010 ident: 10.1016/j.lfs.2019.116577_bb0085 article-title: Simultaneous quantitative determination of N(G),N(G)-dimethyl-L-arginine or asymmetric dimethylarginine and related pathway's metabolites in biological fluids by ultrahigh-performance liquid chromatography/electrospray ionization-tandem mass specterometry publication-title: Anal. Chim. Acta doi: 10.1016/j.aca.2010.08.011 – volume: 6 start-page: 1 year: 2016 ident: 10.1016/j.lfs.2019.116577_bb0030 article-title: Galectin-3 and inflammation glycobiol publication-title: Insights – volume: 230 start-page: 160 issue: 1 year: 2009 ident: 10.1016/j.lfs.2019.116577_bb0120 article-title: The regulation of inflammation by galectin-3 publication-title: Immunol. Rev. doi: 10.1111/j.1600-065X.2009.00794.x – volume: 16 start-page: 595 year: 2014 ident: 10.1016/j.lfs.2019.116577_bb0130 article-title: Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrinindependent carriers publication-title: Nat. Cell Biol. doi: 10.1038/ncb2970 – volume: 10 start-page: 209 year: 2012 ident: 10.1016/j.lfs.2019.116577_bb0105 article-title: Prevalence of inflammatory markers (high-sensitivity C-reactive protein, nuclear factor-κB and adiponectin) in Indian patients with type 2 diabetes mellitus with and without macrovascular complications publication-title: Metab. Syndr. Relat. Disord. doi: 10.1089/met.2011.0044 – volume: 13 start-page: 70 issue: 2 year: 2017 ident: 10.1016/j.lfs.2019.116577_bb0075 article-title: Publication investigation of the relationships ofobesity with melatonin and dehydroepiandrosterone levels publication-title: Nobel Medicus – volume: 44 start-page: 273 year: 2002 ident: 10.1016/j.lfs.2019.116577_bb0070 article-title: Detection method of serum and urine neopterin levels by high performance liquid chromatography and clinical applications publication-title: Gulhane MJ |
| SSID | ssj0005573 |
| Score | 2.4317074 |
| Snippet | Galectin-3 is associated with the process of inflammation and fibrosis. The aim of this study was both to evaluate of galectin-3, methylated arginines and... Purpose Galectin-3 is associated with the process of inflammation and fibrosis. The aim of this study was both to evaluate of galectin-3, methylated arginines... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 116577 |
| SubjectTerms | Adult Arginine Arginine - blood Biomarkers - blood blood glucose Blood Glucose - metabolism blood serum C-Reactive Protein - metabolism Chemiluminescence Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Fasting - blood Female Fibrosis Galectin 3 - analysis Galectin 3 - blood Galectin-3 galectins Glucose Glucose tolerance Glucose Tolerance Test glucose tolerance tests Glycated Hemoglobin A - metabolism Humans Immunoassay immunoassays inflammation Insulin Resistance Male Mass spectrometry Mass spectroscopy Methylated arginines Methylation Microparticles Middle Aged Neopterin noninsulin-dependent diabetes mellitus Organic chemistry patients Prediabetes Prediabetic State - blood tandem mass spectrometry Type 2 diabetes |
| Title | Assessment of serum galectin-3, methylated arginine and Hs-CRP levels in type 2 diabetes and prediabetes |
| URI | https://dx.doi.org/10.1016/j.lfs.2019.116577 https://www.ncbi.nlm.nih.gov/pubmed/31211997 https://www.proquest.com/docview/2283953335 https://www.proquest.com/docview/2243497926 https://www.proquest.com/docview/2253261896 |
| Volume | 231 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxELbaVEhcEC2vQKmMxAEQbtev2D5GEVUAUSFEpdxW3tguQWET5XHohd_OzK43iENz4Lj2WOv1jD3f2uNvCHkNZuED4HaGVCVMWeeZq2xgEXwx_I5IWzm8jfzlajC-Vp8menJARt1dGAyrzGt_u6Y3q3UuucijebGczfCOr1BSNBAESU0mh-RIwBtsjxwNP34eX_2N9ND5oFkohg26w80mzGuekLSbu3PkoTHmLvd0F_xs3NDlQ_Ig40c6bLt4TA5ifULutRklb0_IcZ6ra_omE0q_fUR-DHf0m3SRKBjd9hdFzwBrXc3ke4pppG_ngDoD9asbTBkRqa8DHa_Z6NtXOsfAojWd1RQ3bKmg3YZtI7Rcxe75Mbm-_PB9NGY5wwKbKq42bGpiYV00ySUeuTWVk9FFK1KlrQ3OByHTgIfCpKISEZCUCVF4HabcpAAF8gnp1Ys6PiM0hQLqtTcDnVRIwcYiJQNwUUrvgud9UnQDW04z_ThmwZiXXZzZzxJ0UaIuylYXffJu12TZcm_sE1adtsp_DKgE37Cv2Wmn2TLPXqgHzIVht1L3yatdNcw7PEzxdVxsUUZJ5YwTg30yGtAxtw5knrZWs_sQ2XDrOfP8__r9gtzHJ9zd5vqU9DarbXwJ8GhTnZHD89_8LE-CP35RC8E |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NToi9IDY-VtjASDwAwlsSJ7X9WFWbMrZVCG1S3yKntqGopFU_Hvbfc5c4RXtYH_YY-ywlvjvfL_b5dwCf0CyMRdzOiaqEp0obrktlucNYjL8jQpWabiNfD3v5bfp9lI12YNDehaG0yrD2N2t6vVqHltMwm6fzyYTu-CapSGoIQqQmoyewm1JR6w7s9i8u8-H_TI8sHDQnKacB7eFmneY19UTaHesT4qGR8qHw9BD8rMPQ-Qt4HvAj6zevuA87rjqAp01FybsD2A--umSfA6H0l5fwu7-h32Qzz9Do1n8ZRQZc6youvjEqI303RdRpmVn8opIRjpnKsnzJBz9_sCklFi3ZpGK0YcsS1m7Y1kLzhWufX8Ht-dnNIOehwgIf40St-Fi6SGknvfaxi5UstXDaqcSXmVJWG5sI34ttJH1UJg6RlLQuMZkdx9JbbBCvoVPNKncIzNsI-zMje5lPrbfKRd5LhItCGG1N3IWondhiHOjHqQrGtGjzzP4UqIuCdFE0uujC182QecO9sU04bbVV3DOgAmPDtmFHrWaL4L3Yj5iL0m5F1oWPm270OzpMMZWbrUkmFamWOultk8kQHcdKo8ybxmo2HyJqbj0t3z7uvT_As_zm-qq4uhhevoM96qGd7jg7gs5qsXbHCJVW5fvgCv8Ayr0Npw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Assessment+of+serum+galectin-3%2C+methylated+arginine+and+Hs-CRP+levels+in+type+2+diabetes+and+prediabetes&rft.jtitle=Life+sciences+%281973%29&rft.au=Atalar%2C+Mehmet+Nuri&rft.au=Abu%C5%9Fo%C4%9Flu%2C+Sedat&rft.au=%C3%9Cnl%C3%BC%2C+Ali&rft.au=Tok%2C+O%C4%9Fuzhan&rft.date=2019-08-15&rft.issn=0024-3205&rft.volume=231+p.116577-&rft_id=info:doi/10.1016%2Fj.lfs.2019.116577&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0024-3205&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0024-3205&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0024-3205&client=summon |